01/13/21 5:01 PMNasdaq : UTHRUnited Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso(R) in Pulmonary Hypertension Associated with Interstitial Lung DiseaseUnited Therapeutics Corporation (Nasdaq: UTHR) today announced that results from the INCREASE clinical study of Tyvaso (R) (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated withRHEA-AIneutral
01/04/21 6:00 AMNasdaq : UTHRUnited Therapeutics Corporation To Present At The 39th Annual J.P. Morgan Healthcare ConferenceUnited Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's businessRHEA-AIneutral
12/28/20 6:00 AMNasdaq : UTHRUnited Therapeutics Announces Agreement To Acquire Priority Review VoucherUnited Therapeutics Corporation (Nasdaq: UTHR) announced today an agreement to acquire a Rare Pediatric Disease Priority Review Voucher (PRV), which it plans to use with a forthcoming New Drug Application (NDA) withRHEA-AIneutral
12/09/20 6:00 AMNasdaq : UTHRUnited Therapeutics Receives FDA Orphan Drug Designation For Treprostinil For The Treatment Of Idiopathic Pulmonary FibrosisUnited Therapeutics Corporation (Nasdaq: UTHR) announced today that the United States Food and Drug Administration (FDA) has granted orphan drug designation to treprostinil for the treatment of patients withRHEA-AIvery positive
11/24/20 6:00 AMNasdaq : UTHRUnited Therapeutics Releases Its First Corporate Responsibility ReportUnited Therapeutics Corporation (Nasdaq: UTHR) today announced the release of its initial Corporate Responsibility Report with primarily 2019 data and selected 2020 highlights, providing stakeholders importantRHEA-AIneutral
11/10/20 6:00 AMNasdaq : UTHRUnited Therapeutics Corporation To Present At The Jefferies Virtual London Healthcare ConferenceUnited Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's businessRHEA-AIneutral
11/02/20 5:55 AMNasdaq : UTHRUnited Therapeutics Corporation To Present At The Credit Suisse 29th Annual Virtual Healthcare ConferenceUnited Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, will provide an overview and update on the company's businessRHEA-AIneutral
10/28/20 6:00 AMNasdaq : UTHRUnited Therapeutics Corporation Reports Third Quarter 2020 Financial ResultsUnited Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended September 30, 2020. "As our core business continues to perform well, we have a solid footing to enter 2021RHEA-AIneutral
10/22/20 6:00 AMNasdaq : UTHRUnited Therapeutics Highlights Poster Presentations from the Recent CHEST 2020 MeetingUnited Therapeutics Corporation (Nasdaq: UTHR) today announced new clinical data on Tyvaso (R) (treprostinil) Inhalation Solution in patients with pulmonary hypertension associated with interstitial lung diseaseRHEA-AIneutral
10/21/20 6:00 AMNasdaq : UTHRUnited Therapeutics Corporation To Report Third Quarter 2020 Financial Results Before The Market Opens On Wednesday, October 28, 2020United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2020 financial results before the market opens on Wednesday, October 28, 2020.United Therapeutics will host aRHEA-AIneutral
